SCHEMBL3014241

SCHEMBL3014241

Cc1cc(C)c(S(=O)(=O)N2CCN(c3nc(Cc4c(C)cccc4C)cs3)CC2)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
MAPK1 P28482 2/20 0.42
LMNA P02545 1/20 0.42
KDM4E B2RXH2 2/20 0.40
EBP Q15125 1/20 0.39
DHCR7 Q9UBM7 1/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.39
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020591 0.94 NPSR1 (0.48) NPSR1GAATSHRALDH1A1KMT2A
SCHEMBL3008940 0.90 MEN1 (0.46) NPSR1GAATSHRALDH1A1KMT2A
SCHEMBL3009137 0.89 KMT2A (0.42) NPSR1GAATSHRALDH1A1KMT2A
SCHEMBL3010166 0.89 PKM (0.45) GAATSHRALDH1A1KMT2AMEN1
SCHEMBL3010689 0.89 NPSR1 (0.43) NPSR1GAATSHRALDH1A1KMT2A
SCHEMBL3013060 0.88 NPSR1 (0.43) NPSR1GAATSHRALDH1A1KMT2A
SCHEMBL3015942 0.88 ALDH1A1 (0.42) GAATSHRALDH1A1KMT2AMEN1
SCHEMBL3012895 0.88 PKM (0.48) GAATSHRALDH1A1KMT2AMEN1
SCHEMBL3016140 0.88 EBP (0.48) NPSR1GAATSHRALDH1A1KMT2A
SCHEMBL3015981 0.86 KMT2A (0.45) NPSR1GAATSHRALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA NPSR1 764/4885GAA 110/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.